Bottom line, if insurance companies decide to pay part of the cost, seems most likely, users would have a higher co-pay, then instead of 60% audience one might look at an 80% figure. I consider the convience part,
xubera's clinical advantages over injected insulin do not appear to extend beyond patient convenience - a feature not traditionally highly valued by third-party payors.,
to be what it is all about anyway. That is what will drive sales. The American Diabetes Assoc. stated they were behind Exubera because, many more diabetics will use insulin than currently do. They said this because it removes the fear of needles, inconvience of refrigeration etc. Meaning, there is a much much larger potential user base than is currently indicated. If the audience were to double, type 2 diabetes is growing expotentially, then even using the crappy numbers below, 60%, one would still have 120% of the existing user base. It amazes me how jounalist, ????, use only the data they choose, to justify their article. Sorry, but I am not impressed with the poor reasoning abilities of this mental midget. I am not discounting the below article because I am closed minded. I am because, they left out most of the facts.
Market Data 
Markets 
AI
